MBX Biosciences logo
MBX Biosciences
MBX | NASDAQ
Chart Builder DCF Calculator
$53.12
-$2.82 (-5.04%)
At close: Nov 16, 2026, 4:00 PM ET
$53.12
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

MBX Biosciences Company Profile

Company profile explained

Company Profile

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Key Executives

Name Position
Steven L. Hoerter Executive Chairperson, CEO & President
Jeffrey Held Chief Legal Officer
John W. Smither Chief Financial Officer
Andreas Moraitis Senior Vice President of Clinical Development
Chatan Charan Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls
Karen Basbaum Chief Business Officer
Mark Hope Chief Regulatory & Quality Officer
Mark R. Soued Chief Commercial Officer
Michael A. Dorato DABT Sr. Vice President of Discovery & Non-Clinical Development
Michelle Graham Chief Human Resources Officer
Pete De Spain Senior Vice President of Investor Relations & Corporate Communications
Salomon Azoulay Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 22, 2026 4 Filing
Oct 22, 2026 3 Filing
Oct 22, 2026 8-K Current Report
Aug 27, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 SC 13D/A [Amend] Filing
Aug 10, 2026 SC 13D/A [Amend] Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 05, 2026 4 Filing
View All SEC Filings ➞
MBX Biosciences
MBX Biosciences logo
Country United States
IPO Date Sep 13, 2024
Industry Biotechnology
Sector Healthcare
Employees 63
CEO Steve Hoerter

Contact Details

11711 N. Meridian Street Carmel, Indiana 46032 United States

Stock Details

Ticker Symbol MBX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001776111
CUSIP Number 55287L101
ISIN Number US55287L1017
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.